Cpd E-module MCQs - Professor C.E. Clarke

11 Questions | Total Attempts: 89

SettingsSettingsSettings
Please wait...
Professor Quizzes & Trivia

Questions and Answers
  • 1. 
    The TEMPO and ADAGIO delayed-start design trials raised the prospect that rasagiline has a disease modifying effect in Parkinson's disease. Arguments against this include:
    • A. 

      Inconsistent results with the 1 mg/d and 2 mg/d results in the two trials

    • B. 

      Lack of clinical significance of the results

    • C. 

      Absence of quality of life data

    • D. 

      Absence of health economics analysis

    • E. 

      All of the above

  • 2. 
    Possible treatments for early Parkinson's disease with functional disability DO NOT include:
    • A. 

      Levodopa preparations

    • B. 

      Dopamine agonists

    • C. 

      Monoamine oxidase B inhibitors

    • D. 

      Levodopa with a catechol-O-methyl transferase inhibitor

    • E. 

      All of the above

  • 3. 
    Prolonged-release dopamine agonists are UNLIKELY to be useful in patients with Parkinson's disease who have:
    • A. 

      Poor compliance

    • B. 

      Nocturnal akinesia

    • C. 

      Severe motor fluctuations

    • D. 

      Early morning akinesia

    • E. 

      All of the above

  • 4. 
    A systematic review of trials examining the efficacy and safety of treatments for advanced Parkinson's disease has NOT shown:
    • A. 

      Any trials comparing apomorphine infusion, deep brain stimulation surgery, and intestinal levodopa gel infusion in randomised controlled trials

    • B. 

      Positive randomised controlled trials of apomorphine infusion versus best medical therapy

    • C. 

      Positive randomised controlled trials of deep brain stimulation surgery and intestinal levodopa gel infusion versus best medical therapy

    • D. 

      Positive effects of deep brain stimulation surgery on quality of life

    • E. 

      None of the above

  • 5. 
    Which of the following statements is true of rehabilitation therapies in Parkinson's disease:
    • A. 

      Further trials of all rehabilitation therapies are required at all stages of the disease

    • B. 

      There is firm evidence of the efficacy of physiotherapy and occupational therapy in the early stages of the disease

    • C. 

      There is firm evidence of the efficacy of physiotherapy and occupational therapy in the later stages of the disease

    • D. 

      There is firm evidence of the efficacy and cost effectiveness of Lee Silverman Voice Training in all stages of the disease

    • E. 

      There is firm evidence of the efficacy of traditional NHS speech and language therapy in all stages of the disease.

  • 6. 
    Potential disease modifying therapies in Parkinson's disease undergoing clinical trials DO NOT include:
    • A. 

      Creatine

    • B. 

      Co-enzyme Q10

    • C. 

      Isradipine

    • D. 

      Cogane

    • E. 

      Riluzole

  • 7. 
    Potential new drug classes in Parkinson's disease DO NOT include:
    • A. 

      Adenosine antagonists

    • B. 

      Dopamine antagonists

    • C. 

      Dopamine re-uptake inhibitors

    • D. 

      Partial dopamine agonists

    • E. 

      Alpha-2 noradrenergic antagonists

  • 8. 
    A 63 year old with Parkinson's disease for 7 years has severe off periods. He is otherwise healthy, with no symptoms of dementia. The most effective adjuvant agent is likely to be:
    • A. 

      Entacapone

    • B. 

      Rasagiline

    • C. 

      Amantadine

    • D. 

      Selegiline

    • E. 

      Non-ergot dopamine agonist

  • 9. 
    A fit 74 year old patient with newly diagnosed Parkinson's disease and significant functional disability should be treated with:
    • A. 

      The evidence-base is poor and it is currently uncertain with what such a patient should be treated.

    • B. 

      Non-ergot dopamine agonist

    • C. 

      Levodopa

    • D. 

      Monoamine oxidase B inhibitor

    • E. 

      Amantadine

  • 10. 
    You are asked to see a 59 year old patient with Parkinson's disease for 15 years with severe motor fluctuations. He is taking Stalevo® 100 strength tablets five daily, rotigotine patch 16 mg per day, and amantadine 100 mg three daily. He has a history of severe depression and an early neuropathy with type 2 diabetes. Which of the following statements is NOT true about his possible treatment options:
    • A. 

      Subthalamic deep brain stimulation surgery is inappropriate because it may aggravate his depression and trigger suicidal ideation

    • B. 

      Apomorphine is not appropriate as he is more likely to develop skin nodules

    • C. 

      If given intestinal levodopa gel infusion, the neuropathy should be monitored in case it deteriorates due to interference with vitamin B12 metabolism

    • D. 

      Intestinal levodopa gel infusion is inappropriate because he has not been considered for apomorphine or surgery as per the Summary of Product Characteristics

    • E. 

      Whichever option is chosen, his mental state should be monitored carefully in view of the risk of Parkinson's disease dementia.

  • 11. 
    Which is the only randomised controlled trial in PD that uses measures of sleep as a co-primary endpoint?
    • A. 

      ADAGIO

    • B. 

      EASE- PD

    • C. 

      STRIDE – PD

    • D. 

      RECOVER

    • E. 

      PROUD

Back to Top Back to top